21 results
Primary: Progression free survival.Secondary: Toxicity, overall survival, response rate, duration of response, translational research.
Zie pagina 39-40 van het protocol MO22923 versie 2, 26 Mei 2011
* The primary objective of this study is:- the study of the response rate and the macroscopic and microscopic response charactheristics of neo-adjuvant chemotherapy of patients with peritoneal carcinomatosis (PC) of colorectal origin. * Secundary…
1. To study the effects of bevacizumab on [11C]docetaxel uptake by lung tumours.2. To study the early effects of bevacizumab on tumour blood flow.3. To study the relation between [11C]docetaxel uptake and blood flow in tumours after administration…
Objectives of the phase II study (80 patients) are to explore the feasibility of accrual, the feasibility, safety, and tolerance of perioperative systemic therapy, and the radiological and histological response of colorectal PM to neoadjuvant…
To determine the median progression-free survival (PFS) and R0/1 secondary resection rate upon induction systemic treatment in colorectal cancer patients with initially unresectable liver-only metastases, stratified by RAS and BRAF tumor mutation…
Primary objective:To evaluate the efficacy of atezolizumab plus bevacizumab compared with active surveillance on the basis of recurrence-free survival (RFS).Secondary objectives: 1. To evaluate the efficacy of atezolizumab plus bevacizumab compared…
Dose escalation: To establish the MTD and RP2D of tisotumab vedotin in combination in subjects with cervical cancer Dose expansion: Evaluate the antitumor activity of tisotumab vedotin monotherapy and incombination in subjects with cervical cancer
Study MX39795 will compare the efficacy and safety of molecularly-guided therapy versusstandard platinum-containing chemotherapy in patients with poor prognosis cancer of unknown primary site(CUP; non-specific subset) who have achieved disease…
To compare two (standard) treatment regimens in patients with KRAS mutated advanced stage NSCLC as first line treatment.
This study has 2 primary objectives:1) To determine the time point of induction of VEGF expression in the tumour tissue of oesophagus carcinomas during chemoradiation. 2) To determine whether the tumour promoting effects of this induction of VEGF…
The primary objective of this study is to determine the anti-tumor activity, as measured by overall response rate (ORR) of atezolizumab in combination with bevacizumab in patients with chemotherapy resistant CRC and positivity for MSI-like molecular…
Objective: To compare pembrolizumab plus paclitaxel with or without bevacizumab to placebo plus paclitaxel with or without bevacizumab, withrespect to progression-free survival (PFS) per RECIST 1.1 as assessed by the investigator.
Modified objectives after implementation of protocol amendment February 2017: Primary: 1. Validate the BRCA-like test* in predicting differential PFS with first line alkylating and platinum agents when compared to paclitaxel in TNBC Secondary: 1.…
Primary:- To test whether bevacizumab added to a backbone chemotherapy regimen (temozolomide or irinotecan-temozolomide or topotecan-temozolomide) demonstrates activity in children with relapsed or refractory neuroblastoma- To test whether the…
*- To explore efficacy of neoadjuvant atezolizumab and bevacizumab following radiotherapy in low- to intermediate-risk rectal cancer• To evaluate safety/tolerability and pre-operative treatment-related complications with atezolizumab and bevacizumab…
The primary objective of this study is to compare overall survival rates of CRC patients with multi-organ metastases with indication for first line palliative systemic treatment for mCRC, randomized for treatment with combination chemotherapy or…
The aim of this prospective single-arm phase II study is to evaluate the efficacy of amivantamab and bevacizumab added to continued treatment with a third-generation EGFRTKI (osimertinib or lazertinib), for patients with EGFR-mutant advanced NSCLC,…
This Phase Ia/Ib study will evaluate the safety, pharmacokinetics, immunogenicity (as applicable for study biotherapeutics), preliminary activity, and biomarkers of GDC-6036 as a single agent (Arm A) and in combination with other anti-cancer…
To evaluate the efficacy and safety of tucatinib in combination with trastuzumab and mFOLFOX6 in comparison to mFOLFOX6 given with or without either bevacizumab or cetuximab as first-line (1L) treatment in adults with HER2 positive (HER2+)…